Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Sana Biotechnology, Inc.SANA · Entity 4870 | EVP, Chief Business Officer | March 07, 2024 | March 08, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Sana Biotechnology, Inc.
Report date March 07, 2024 · Filed March 08, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 37,500 |
Reported balance
After 2024-03-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-03-07 · Grant · Acquired 37,500 · Balance 37,500 F1: Each restricted stock unit represents a contingent right to receive one share of Sana Biotechnology, Inc. ("Sana") common stock. F2: The restricted stock units vest in four equal installments on each of March 7, 2025, 2026, 2027 and 2028, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.58 · Expires 2034-03-06 | Direct | 168,750 |
Reported balance
After 2024-03-07 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-03-07 · Grant · Acquired 168,750 · Balance 168,750 F3: The option vests and becomes exercisable as to 25% of the underlying shares on March 7, 2025 and in 36 equal monthly installments thereafter, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of Sana Biotechnology, Inc. ("Sana") common stock.
F2: The restricted stock units vest in four equal installments on each of March 7, 2025, 2026, 2027 and 2028, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.
F3: The option vests and becomes exercisable as to 25% of the underlying shares on March 7, 2025 and in 36 equal monthly installments thereafter, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 07, 2024 Filed Mar 8, 2024 21:17 UTC | Sana Biotechnology, Inc. SANA · Entity 4870 | GrantStock Option (Right to Buy) · Derivative | 168,750 | $0.00 Strike: $9.58 | $0.00 |
DisclosureSEC source: 0001562180-24-002477 · primarydocument.xml · derivative · entry 2 Hordo Christian · CIK 0001830070 · EVP, Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 168,750 Underlying: Common Stock · 168,750 shares Expires 2034-03-06 F3 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the underlying shares on March 7, 2025 and in 36 equal monthly installments thereafter, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date. Read SEC document |
| March 07, 2024 Filed Mar 8, 2024 21:17 UTC | Sana Biotechnology, Inc. SANA · Entity 4870 | GrantRestricted Stock Units · Derivative | 37,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-002477 · primarydocument.xml · derivative · entry 1 Hordo Christian · CIK 0001830070 · EVP, Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,500 Underlying: Common Stock · 37,500 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Sana Biotechnology, Inc. ("Sana") common stock. F2 · derivative.exercise_date: The restricted stock units vest in four equal installments on each of March 7, 2025, 2026, 2027 and 2028, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date. F2 · derivative.expiration_date: The restricted stock units vest in four equal installments on each of March 7, 2025, 2026, 2027 and 2028, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date. Read SEC document |
| December 15, 2023 Filed Dec 18, 2023 21:51 UTC | Sana Biotechnology, Inc. SANA · Entity 4870 | SaleCommon Stock | 75,000 | $4.00 | $300,097.50 |
DisclosureSEC source: 0001562180-23-008445 · primarydocument.xml · nonDerivative · entry 1 Hordo Christian · CIK 0001830070 · EVP, Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 867,455 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 4, 2021, as modified on April 11, 2023. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $3.93 to $4.10, inclusive. The reporting person undertakes to provide to Sana Biotechnology, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 02, 2023 Filed Nov 3, 2023 20:08 UTC | Sana Biotechnology, Inc. SANA · Entity 4870 | GrantRestricted Stock Units · Derivative | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-23-007550 · primarydocument.xml · derivative · entry 1 Hordo Christian · CIK 0001830070 · EVP, Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Sana Biotechnology, Inc. ("Sana") common stock. F2 · derivative.exercise_date: The restricted stock units will vest in full on January 2, 2025, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through such date. F2 · derivative.expiration_date: The restricted stock units will vest in full on January 2, 2025, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through such date. Read SEC document |
| March 02, 2023 Filed Mar 3, 2023 21:36 UTC | Sana Biotechnology, Inc. SANA · Entity 4870 | GrantStock Options (Right to Buy) · Derivative | 185,000 | $0.00 Strike: $3.76 | $0.00 |
DisclosureSEC source: 0001562180-23-002398 · primarydocument.xml · derivative · entry 1 Hordo Christian · CIK 0001830070 · EVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,000 Underlying: Common Stock · 185,000 shares Expires 2033-03-01 F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the underlying shares on March 2, 2024 and in 36 equal monthly installments thereafter. Read SEC document |
| March 03, 2022 Filed Mar 8, 2022 14:05 UTC | Sana Biotechnology, Inc. SANA · Entity 4870 | GrantStock Options (Right to Buy) · Derivative | 225,000 | $0.00 Strike: $5.70 | $0.00 |
DisclosureSEC source: 0001562180-22-002427 · primarydocument.xml · derivative · entry 1 Hordo Christian · CIK 0001830070 · EVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,000 Underlying: Common Stock · 225,000 shares Expires 2032-03-02 F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the underlying shares on March 3, 2023 and in 36 equal monthly installments thereafter. Read SEC document |
| September 10, 2021 Filed Sep 14, 2021 20:05 UTC | Sana Biotechnology, Inc. SANA · Entity 4870 | SaleCommon Stock | 1,477 | $25.00 | $36,925.00 |
DisclosureSEC source: 0001562180-21-005940 · primarydocument.xml · nonDerivative · entry 1 Hordo Christian · CIK 0001830070 · EVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 942,455 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 4, 2021. Read SEC document |
| September 09, 2021 Filed Sep 10, 2021 23:27 UTC | Sana Biotechnology, Inc. SANA · Entity 4870 | Exercise / conversionStock Option (Right to Buy) · Derivative | 39,205 | $0.00 Strike: $1.48 | $0.00 |
DisclosureSEC source: 0001562180-21-005916 · primarydocument.xml · derivative · entry 4 Hordo Christian · CIK 0001830070 · EVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,803 Underlying: Common Stock · 39,205 shares Expires 2030-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option began vesting on February 14, 2020, with 25% of the underlying shares becoming vested and exercisable on February 14, 2021 and the remainder of the underlying shares vesting at a rate of 1/36th per month thereafter. Read SEC document |
| September 09, 2021 Filed Sep 10, 2021 23:27 UTC | Sana Biotechnology, Inc. SANA · Entity 4870 | SaleCommon Stock | 25,466 | $25.01 | $636,856.27 |
DisclosureSEC source: 0001562180-21-005916 · primarydocument.xml · nonDerivative · entry 3 Hordo Christian · CIK 0001830070 · EVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 943,932 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 4, 2021. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.00 to $25.04, inclusive. Read SEC document |
| September 09, 2021 Filed Sep 10, 2021 23:27 UTC | Sana Biotechnology, Inc. SANA · Entity 4870 | SaleCommon Stock | 39,205 | $25.01 | $980,634.67 |
DisclosureSEC source: 0001562180-21-005916 · primarydocument.xml · nonDerivative · entry 2 Hordo Christian · CIK 0001830070 · EVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 969,398 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 4, 2021. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.00 to $25.18, inclusive. The reporting person undertakes to provide to Sana Biotechnology, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4. Read SEC document |
| September 09, 2021 Filed Sep 10, 2021 23:27 UTC | Sana Biotechnology, Inc. SANA · Entity 4870 | Exercise / conversionCommon Stock | 39,205 | $1.48 | $58,023.40 |
DisclosureSEC source: 0001562180-21-005916 · primarydocument.xml · nonDerivative · entry 1 Hordo Christian · CIK 0001830070 · EVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,008,603 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 03, 2021 Filed Sep 7, 2021 23:29 UTC | Sana Biotechnology, Inc. SANA · Entity 4870 | Exercise / conversionStock Option (Right to Buy) · Derivative | 700 | $0.00 Strike: $1.48 | $0.00 |
DisclosureSEC source: 0001562180-21-005865 · primarydocument.xml · derivative · entry 7 Hordo Christian · CIK 0001830070 · EVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,008 Underlying: Common Stock · 700 shares Expires 2030-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option began vesting on February 14, 2020, with 25% of the underlying shares becoming vested and exercisable on February 14, 2021 and the remainder of the underlying shares vesting at a rate of 1/36th per month thereafter. Read SEC document |
| September 03, 2021 Filed Sep 7, 2021 23:29 UTC | Sana Biotechnology, Inc. SANA · Entity 4870 | SaleCommon Stock | 700 | $25.00 | $17,500.00 |
DisclosureSEC source: 0001562180-21-005865 · primarydocument.xml · nonDerivative · entry 5 Hordo Christian · CIK 0001830070 · EVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 969,398 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 4, 2021. Read SEC document |
| September 03, 2021 Filed Sep 7, 2021 23:29 UTC | Sana Biotechnology, Inc. SANA · Entity 4870 | Exercise / conversionCommon Stock | 700 | $1.48 | $1,036.00 |
DisclosureSEC source: 0001562180-21-005865 · primarydocument.xml · nonDerivative · entry 4 Hordo Christian · CIK 0001830070 · EVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 970,098 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 02, 2021 Filed Sep 7, 2021 23:29 UTC | Sana Biotechnology, Inc. SANA · Entity 4870 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,558 | $0.00 Strike: $1.48 | $0.00 |
DisclosureSEC source: 0001562180-21-005865 · primarydocument.xml · derivative · entry 6 Hordo Christian · CIK 0001830070 · EVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,708 Underlying: Common Stock · 6,558 shares Expires 2030-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option began vesting on February 14, 2020, with 25% of the underlying shares becoming vested and exercisable on February 14, 2021 and the remainder of the underlying shares vesting at a rate of 1/36th per month thereafter. Read SEC document |
| September 02, 2021 Filed Sep 7, 2021 23:29 UTC | Sana Biotechnology, Inc. SANA · Entity 4870 | SaleCommon Stock | 1,400 | $25.00 | $35,005.46 |
DisclosureSEC source: 0001562180-21-005865 · primarydocument.xml · nonDerivative · entry 3 Hordo Christian · CIK 0001830070 · EVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 969,398 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 4, 2021. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.00 to $25.015, inclusive. Read SEC document |
| September 02, 2021 Filed Sep 7, 2021 23:29 UTC | Sana Biotechnology, Inc. SANA · Entity 4870 | SaleCommon Stock | 6,558 | $25.00 | $163,962.46 |
DisclosureSEC source: 0001562180-21-005865 · primarydocument.xml · nonDerivative · entry 2 Hordo Christian · CIK 0001830070 · EVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 970,798 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 4, 2021. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.00 to $25.02, inclusive. The reporting person undertakes to provide to Sana Biotechnology, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4. Read SEC document |
| September 02, 2021 Filed Sep 7, 2021 23:29 UTC | Sana Biotechnology, Inc. SANA · Entity 4870 | Exercise / conversionCommon Stock | 6,558 | $1.48 | $9,705.84 |
DisclosureSEC source: 0001562180-21-005865 · primarydocument.xml · nonDerivative · entry 1 Hordo Christian · CIK 0001830070 · EVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 977,356 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 20:12 UTC | Sana Biotechnology, Inc. SANA · Entity 4870 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,134 | $0.00 Strike: $1.48 | $0.00 |
DisclosureSEC source: 0001562180-21-005810 · primarydocument.xml · derivative · entry 4 Hordo Christian · CIK 0001830070 · EVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,266 Underlying: Common Stock · 1,134 shares Expires 2030-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option began vesting on February 14, 2020, with 25% of the underlying shares becoming vested and exercisable on February 14, 2021 and the remainder of the underlying shares vesting at a rate of 1/36th per month thereafter. Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 20:12 UTC | Sana Biotechnology, Inc. SANA · Entity 4870 | SaleCommon Stock | 3,002 | $25.01 | $75,067.11 |
DisclosureSEC source: 0001562180-21-005810 · primarydocument.xml · nonDerivative · entry 3 Hordo Christian · CIK 0001830070 · EVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 970,798 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 4, 2021. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.00 to $25.03, inclusive. Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 20:12 UTC | Sana Biotechnology, Inc. SANA · Entity 4870 | SaleCommon Stock | 1,134 | $25.00 | $28,354.08 |
DisclosureSEC source: 0001562180-21-005810 · primarydocument.xml · nonDerivative · entry 2 Hordo Christian · CIK 0001830070 · EVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 973,800 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 4, 2021. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.00 to $25.02, inclusive. The reporting person undertakes to provide to Sana Biotechnology, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4. Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 20:12 UTC | Sana Biotechnology, Inc. SANA · Entity 4870 | Exercise / conversionCommon Stock | 1,134 | $1.48 | $1,678.32 |
DisclosureSEC source: 0001562180-21-005810 · primarydocument.xml · nonDerivative · entry 1 Hordo Christian · CIK 0001830070 · EVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 974,934 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 30, 2021 Filed Sep 1, 2021 20:20 UTC | Sana Biotechnology, Inc. SANA · Entity 4870 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,100 | $0.00 Strike: $1.48 | $0.00 |
DisclosureSEC source: 0001562180-21-005697 · primarydocument.xml · derivative · entry 4 Hordo Christian · CIK 0001830070 · EVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,400 Underlying: Common Stock · 1,100 shares Expires 2030-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option began vesting on February 14, 2020, with 25% of the underlying shares becoming vested and exercisable on February 14, 2021 and the remainder of the underlying shares vesting at a rate of 1/36th per month thereafter. Read SEC document |
| August 30, 2021 Filed Sep 1, 2021 20:20 UTC | Sana Biotechnology, Inc. SANA · Entity 4870 | SaleCommon Stock | 1,200 | $25.02 | $30,021.96 |
DisclosureSEC source: 0001562180-21-005697 · primarydocument.xml · nonDerivative · entry 3 Hordo Christian · CIK 0001830070 · EVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 973,800 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 4, 2021. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.000 to $25.025, inclusive. Read SEC document |
| August 30, 2021 Filed Sep 1, 2021 20:20 UTC | Sana Biotechnology, Inc. SANA · Entity 4870 | SaleCommon Stock | 1,100 | $25.01 | $27,511.00 |
DisclosureSEC source: 0001562180-21-005697 · primarydocument.xml · nonDerivative · entry 2 Hordo Christian · CIK 0001830070 · EVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 975,000 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 4, 2021. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.00 to $25.03, inclusive. The reporting person undertakes to provide to Sana Biotechnology, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission upon request full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4. Read SEC document |
| August 30, 2021 Filed Sep 1, 2021 20:20 UTC | Sana Biotechnology, Inc. SANA · Entity 4870 | Exercise / conversionCommon Stock | 1,100 | $1.48 | $1,628.00 |
DisclosureSEC source: 0001562180-21-005697 · primarydocument.xml · nonDerivative · entry 1 Hordo Christian · CIK 0001830070 · EVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 976,100 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.